Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of ...

Check the time stamp on this data. Updated AI-Generated Signals for Surrozen Inc. (SRZN) available here: SRZN. Type a few ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Guggenheim upgraded Surrozen (SRZN) to Buy from Neutral with a $45 price target. Recent Phase 1b data for SZN-043, the company's lead asset for liver disease, was "encouraging," says the analyst.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...